BioCentury
ARTICLE | Clinical News

Annamycin regulatory update

July 4, 2005 7:00 AM UTC

FDA granted Orphan Drug designation to annamycin, a second-generation anthracycline, to treat acute lymphoblastic leukemia (ALL). Annamycin completed a Phase I/IIa trial in refractory leukemia. ...